×

Metabolites of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile

  • US 8,889,697 B2
  • Filed: 10/07/2010
  • Issued: 11/18/2014
  • Est. Priority Date: 06/13/2007
  • Status: Active Grant
First Claim
Patent Images

1. A method of treating cancer in a patient, comprising administering to said patient a therapeutically effective amount of a compound selected from the group consisting of:

  • 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-y1)-1H-pyrazol-1-y1)-3-(3-hydroxycyclopentyl)propanenitrile;

    3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-y1)-1H-pyrazol-1-y1)-3-(2-hydroxycyclopentyl)propanenitrile; and

    3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-y1)-1H-pyrazol-1-y1)-3-oxocyclopentyl)propanenitrile,or a pharmaceutically acceptable salt thereof;

    wherein said cancer is pancreatic cnacer, chronic myelogenous leukemia (CML), acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), or chronic myelomonocytic leukemia (CMML); and

    wherein said treating refers to ameliorating or inhibiting the disease in a patient.

View all claims
  • 3 Assignments
Timeline View
Assignment View
    ×
    ×